Loading news...
MDxHealth (NASDAQ: MDXH - Get Free Report) and Health Catalyst (NASDAQ: HCAT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Volatility and Risk MDxHealth has a beta of
Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.04 per share a year ago.
Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript
SALT LAKE CITY, March 12, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2025. “We closed 2025 with solid performance across our business, including total revenue of $311.1 million and Adjusted EBITDA of $41.4 million,” said Ben Albert, CEO of Health Catalyst “In 2026, we are focused on the future and on positioning Health Catalyst for long‑term success.
Health Catalyst (HCAT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Besides Wall Street's top-and-bottom-line estimates for Health Catalyst (HCAT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its fourth quarter and year end 2025 operating results on Thursday, March 12, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.
Albert to Sharpen Focus on Improving Cost and Operational Efficiency, Clinical Quality, and Consumer Experience in Healthcare Health Catalyst Board to be Reduced to Five Directors Immediately Prior to the 2026 Annual Meeting SALT LAKE CITY, Feb. 18, 2026 /PRNewswire/ -- Health Catalyst, Inc. (Nasdaq: HCAT) ("Health Catalyst" or the "Company"), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Ben Albert, the Company's President and Chief Operating Officer (COO), was appointed to serve as Chief Executive Officer (CEO) and as a member of Health Catalyst's Board of Directors ( "Board"), effective February 12, 2026. In connection with the appointment, Health Catalyst accelerated the timing of its previously announced succession plan for Dan Burton, who has stepped down as CEO and as a member of the Board.
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Health Catalyst (HCAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Healthcare Triangle (NASDAQ: HCTI - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings. Profitability This table compares Health Catalyst and
Health Catalyst (HCAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Shares of Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) have been assigned a consensus recommendation of "Hold" from the fourteen ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to
AMH Equity Ltd boosted its holdings in Health Catalyst, Inc. (NASDAQ: HCAT) by 54.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 660,000 shares of the company's stock after buying an additional 232,851 shares during the quarter. Health Catalyst makes up
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Healthcare Triangle (NASDAQ: HCTI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, dividends, earnings and risk. Risk and Volatility Health Catalyst has a
Shares of Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) have been assigned a consensus rating of "Hold" from the fourteen research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and five have issued a buy
Health Catalyst (NASDAQ: HCAT - Get Free Report) and Precipio (NASDAQ: PRPO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings and dividends. Volatility and Risk Health Catalyst has a beta
HeartSciences (NASDAQ: HSCS - Get Free Report) and Health Catalyst (NASDAQ: HCAT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Profitability This table compares HeartSciences and Health Catalyst's